Medicinal and recreational marijuana use among HIV-infected women in the Women's interagency HIV study (WIHS) cohort, 1994-2010

Gypsyamber D'Souza, Pamela A. Matson, Cynthia D. Grady, Shadi Nahvi, Dan Merenstein, Kathleen M. Weber, Ruth Greenblatt, Pam Burian, Tracey E. Wilson

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Despite the major benefits of effective antiretroviral therapy on HIV-related survival, there is an ongoing need to help alleviate medication side effects related to antiretroviral therapy use. Initial studies suggest that marijuana use may reduce HIV-related symptoms, but medical marijuana use among HIV-infected individuals has not been well described. Methods: The authors evaluated trends in marijuana use and reported motivations for use among 2776 HIV-infected women in the Women's Interagency HIV Study between October 1994 and March 2010. Predictors of any and daily marijuana use were explored in multivariate logistic regression models clustered by person using generalized estimating equation. In 2009, participants were asked if their marijuana use was medical, "meaning prescribed by a doctor," or recreational, or both. Results: Over the 16 years of this study, the prevalence of current marijuana use decreased significantly from 21% to 14%. In contrast, daily marijuana use almost doubled from 3.3% to 6.1% of all women and from 18% to 51% of current marijuana users. Relaxation, appetite improvement, reduction of HIV-related symptoms, and social use were reported as common reasons for marijuana use. In 2009, most marijuana users reported either purely medicinal use (26%) or both medicinal and recreational usage (29%). Daily marijuana use was associated with higher CD4 cell count, quality of life, and older age. Demographic characteristics and risk behaviors were associated with current marijuana use overall but were not predictors of daily use. Conclusions: This study suggests that both recreational and medicinal marijuana use are relatively common among HIV-infected women in the United States.

Original languageEnglish (US)
Pages (from-to)618-626
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume61
Issue number5
DOIs
StatePublished - Dec 15 2012

Fingerprint

Medical Marijuana
Cannabis
Cohort Studies
HIV
Logistic Models
Appetite
CD4 Lymphocyte Count
Risk-Taking
Motivation

Keywords

  • Cannabis
  • HIV
  • Marijuana
  • Medicinal

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Medicinal and recreational marijuana use among HIV-infected women in the Women's interagency HIV study (WIHS) cohort, 1994-2010. / D'Souza, Gypsyamber; Matson, Pamela A.; Grady, Cynthia D.; Nahvi, Shadi; Merenstein, Dan; Weber, Kathleen M.; Greenblatt, Ruth; Burian, Pam; Wilson, Tracey E.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 61, No. 5, 15.12.2012, p. 618-626.

Research output: Contribution to journalArticle

D'Souza, Gypsyamber ; Matson, Pamela A. ; Grady, Cynthia D. ; Nahvi, Shadi ; Merenstein, Dan ; Weber, Kathleen M. ; Greenblatt, Ruth ; Burian, Pam ; Wilson, Tracey E. / Medicinal and recreational marijuana use among HIV-infected women in the Women's interagency HIV study (WIHS) cohort, 1994-2010. In: Journal of Acquired Immune Deficiency Syndromes. 2012 ; Vol. 61, No. 5. pp. 618-626.
@article{f1e8e49a2a5a4d5ea83afb84d2eb3c40,
title = "Medicinal and recreational marijuana use among HIV-infected women in the Women's interagency HIV study (WIHS) cohort, 1994-2010",
abstract = "Background: Despite the major benefits of effective antiretroviral therapy on HIV-related survival, there is an ongoing need to help alleviate medication side effects related to antiretroviral therapy use. Initial studies suggest that marijuana use may reduce HIV-related symptoms, but medical marijuana use among HIV-infected individuals has not been well described. Methods: The authors evaluated trends in marijuana use and reported motivations for use among 2776 HIV-infected women in the Women's Interagency HIV Study between October 1994 and March 2010. Predictors of any and daily marijuana use were explored in multivariate logistic regression models clustered by person using generalized estimating equation. In 2009, participants were asked if their marijuana use was medical, {"}meaning prescribed by a doctor,{"} or recreational, or both. Results: Over the 16 years of this study, the prevalence of current marijuana use decreased significantly from 21{\%} to 14{\%}. In contrast, daily marijuana use almost doubled from 3.3{\%} to 6.1{\%} of all women and from 18{\%} to 51{\%} of current marijuana users. Relaxation, appetite improvement, reduction of HIV-related symptoms, and social use were reported as common reasons for marijuana use. In 2009, most marijuana users reported either purely medicinal use (26{\%}) or both medicinal and recreational usage (29{\%}). Daily marijuana use was associated with higher CD4 cell count, quality of life, and older age. Demographic characteristics and risk behaviors were associated with current marijuana use overall but were not predictors of daily use. Conclusions: This study suggests that both recreational and medicinal marijuana use are relatively common among HIV-infected women in the United States.",
keywords = "Cannabis, HIV, Marijuana, Medicinal",
author = "Gypsyamber D'Souza and Matson, {Pamela A.} and Grady, {Cynthia D.} and Shadi Nahvi and Dan Merenstein and Weber, {Kathleen M.} and Ruth Greenblatt and Pam Burian and Wilson, {Tracey E.}",
year = "2012",
month = "12",
day = "15",
doi = "10.1097/QAI.0b013e318273ab3a",
language = "English (US)",
volume = "61",
pages = "618--626",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Medicinal and recreational marijuana use among HIV-infected women in the Women's interagency HIV study (WIHS) cohort, 1994-2010

AU - D'Souza, Gypsyamber

AU - Matson, Pamela A.

AU - Grady, Cynthia D.

AU - Nahvi, Shadi

AU - Merenstein, Dan

AU - Weber, Kathleen M.

AU - Greenblatt, Ruth

AU - Burian, Pam

AU - Wilson, Tracey E.

PY - 2012/12/15

Y1 - 2012/12/15

N2 - Background: Despite the major benefits of effective antiretroviral therapy on HIV-related survival, there is an ongoing need to help alleviate medication side effects related to antiretroviral therapy use. Initial studies suggest that marijuana use may reduce HIV-related symptoms, but medical marijuana use among HIV-infected individuals has not been well described. Methods: The authors evaluated trends in marijuana use and reported motivations for use among 2776 HIV-infected women in the Women's Interagency HIV Study between October 1994 and March 2010. Predictors of any and daily marijuana use were explored in multivariate logistic regression models clustered by person using generalized estimating equation. In 2009, participants were asked if their marijuana use was medical, "meaning prescribed by a doctor," or recreational, or both. Results: Over the 16 years of this study, the prevalence of current marijuana use decreased significantly from 21% to 14%. In contrast, daily marijuana use almost doubled from 3.3% to 6.1% of all women and from 18% to 51% of current marijuana users. Relaxation, appetite improvement, reduction of HIV-related symptoms, and social use were reported as common reasons for marijuana use. In 2009, most marijuana users reported either purely medicinal use (26%) or both medicinal and recreational usage (29%). Daily marijuana use was associated with higher CD4 cell count, quality of life, and older age. Demographic characteristics and risk behaviors were associated with current marijuana use overall but were not predictors of daily use. Conclusions: This study suggests that both recreational and medicinal marijuana use are relatively common among HIV-infected women in the United States.

AB - Background: Despite the major benefits of effective antiretroviral therapy on HIV-related survival, there is an ongoing need to help alleviate medication side effects related to antiretroviral therapy use. Initial studies suggest that marijuana use may reduce HIV-related symptoms, but medical marijuana use among HIV-infected individuals has not been well described. Methods: The authors evaluated trends in marijuana use and reported motivations for use among 2776 HIV-infected women in the Women's Interagency HIV Study between October 1994 and March 2010. Predictors of any and daily marijuana use were explored in multivariate logistic regression models clustered by person using generalized estimating equation. In 2009, participants were asked if their marijuana use was medical, "meaning prescribed by a doctor," or recreational, or both. Results: Over the 16 years of this study, the prevalence of current marijuana use decreased significantly from 21% to 14%. In contrast, daily marijuana use almost doubled from 3.3% to 6.1% of all women and from 18% to 51% of current marijuana users. Relaxation, appetite improvement, reduction of HIV-related symptoms, and social use were reported as common reasons for marijuana use. In 2009, most marijuana users reported either purely medicinal use (26%) or both medicinal and recreational usage (29%). Daily marijuana use was associated with higher CD4 cell count, quality of life, and older age. Demographic characteristics and risk behaviors were associated with current marijuana use overall but were not predictors of daily use. Conclusions: This study suggests that both recreational and medicinal marijuana use are relatively common among HIV-infected women in the United States.

KW - Cannabis

KW - HIV

KW - Marijuana

KW - Medicinal

UR - http://www.scopus.com/inward/record.url?scp=84873146484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873146484&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e318273ab3a

DO - 10.1097/QAI.0b013e318273ab3a

M3 - Article

C2 - 23011399

AN - SCOPUS:84873146484

VL - 61

SP - 618

EP - 626

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 5

ER -